Published in Ann Intern Med on May 02, 2000
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg (2008) 1.15
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Multiple myeloma: review of 869 cases. Mayo Clin Proc (1975) 4.59
Amyloidosis: review of 236 cases. Medicine (Baltimore) (1975) 3.39
Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc (1983) 3.22
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med (1978) 3.08
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med (1978) 2.70
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med (1970) 2.61
Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol (1991) 2.59
Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol (1996) 2.48
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
"Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med (1982) 2.24
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med (1983) 2.13
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol (1994) 1.88
IgA-induced eosinophil degranulation. J Immunol (1989) 1.82
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Smoldering multiple myeloma. N Engl J Med (1980) 1.77
Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am (1999) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med (1975) 1.70
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood (1985) 1.67
Plasma cell leukemia. Report on 17 cases. Arch Intern Med (1974) 1.66
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) (1991) 1.66
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood (1996) 1.65
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia (2012) 1.60
Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol (2001) 1.59
Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9, 1998. Part 1. Amyloid (1999) 1.59
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med (1981) 1.54
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood (1996) 1.54
Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc (1989) 1.52
Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol (1996) 1.52
Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med (1996) 1.51
Plasma cell leukemia: an evaluation of response to therapy. Am J Med (1987) 1.51
Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys (1989) 1.51
Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc (2000) 1.47
Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc (1993) 1.47
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 1.47
Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A (2000) 1.46
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol (2001) 1.45
Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood (1972) 1.45
Osteosclerotic myeloma and peripheral neuropathy. Neurology (1983) 1.44
Why better prognostic factors for multiple myeloma are needed. Blood (1994) 1.44
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Prevalence of monoclonal protein in peripheral neuropathy. Neurology (1981) 1.41
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Yusuf ibn al-Kindi. JAMA (1975) 1.39
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
Factor-X deficiency in amyloidosis: a critical review. Am J Hematol (1981) 1.38
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia (2011) 1.38
Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol (1989) 1.38
Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia (2001) 1.36
Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg (1992) 1.32
Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation (1991) 1.32
Significance of extreme elevation of erythrocyte sedimentation rate. JAMA (1967) 1.31
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia (2011) 1.31
Long-term survival in multiple myeloma. N Engl J Med (1983) 1.30
Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc (1984) 1.30
Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc (2000) 1.30
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood (1986) 1.29
Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry (1996) 1.28
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Response rates and survival in primary systemic amyloidosis. Blood (1991) 1.27
Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer (1998) 1.26
Melphalan in multiple myeloma. Blood (1967) 1.25
Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol (1985) 1.24
'Benign' monoclonal gammopathy. A misnomer? JAMA (1984) 1.23
Multiple myeloma and acute leukemia associated with alkylating agents. Arch Intern Med (1975) 1.22
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood (1988) 1.21
"Intermediate" cell types and mixed cell proliferation in multiple myeloma: electron microscopic observations. Blood (1966) 1.21
Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med (1988) 1.21
Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc (2001) 1.20
Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med (1982) 1.19
Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma (1998) 1.19
Multiple myeloma: circulating lymphocytes that express plasma cell antigens. Blood (1984) 1.17
Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis (1992) 1.16
Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood (1985) 1.16
Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol (1994) 1.14
Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol (1990) 1.14
Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med (1990) 1.13
The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc (1987) 1.13
Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med (1992) 1.13
Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Intern Med (1988) 1.12
Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res (1993) 1.11
Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology (1997) 1.11
Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol (2001) 1.11
Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med (1999) 1.11
Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med (1998) 1.10
Sun Ssu-Miao (Si miao). JAMA (1981) 1.09